Environment Agency increases checks on water companies in a bid to improve performance in the water industry

Regulators uncovered almost 500 breaches of environmental rules by water companies in the North last year as they carried out a record number of inspections. The Environment Agency said it had expanded its inspections of treatment works, sewage pumping stations and storm overflows, completing more than 3,300 checks of water company assets belonging to United Utilities, Yorkshire Water and Northumbrian Water in the past year.

Inspection teams uncovered 495 permit condition breaches in the North, where companies are failing to comply with environmental legislation. More than 3,000 breaches were found nationally.

Helen Wakeham, director for water at the Environment Agency, said: “Inspections are a vital preventative measure, with our teams issuing over 3,000 individual actions to water companies, including repairing sewage works and upgrading infrastructure. Together, this will drive meaningful improvements in performance, hold persistent offenders to account and ultimately create a cleaner water environment.”

Water minister Emma Hardy added: “Thanks to our investment in the Environment Agency, inspectors are out in force, checking water company assets at unprecedented levels and taking action where standards aren’t met. This greater oversight of water companies coupled with our long-term reforms will prevent problems before they occur and ensure serial offenders are punished, ensuring a healthy, sustainable water system for the future.”

James Wallace, chief executive of campaign group River Action, said: “It is good to see the Government getting serious about water quality, but inspections alone will not fix the problem.

“With prosecutions taking years to reach court and fines far too low, water polluters are not being properly held to account. The upcoming Water Reform Bill is a once-in-a-generation opportunity to reset the system.”

Stephanie Pullan, director of asset management at Yorkshire Water, said: “We remain absolutely committed to achieving 100% compliance at all of our wastewater assets and welcome increased levels of oversight from our regulators. While many of the breaches identified were minor, we take all breaches seriously and act as quickly as possible to remediate any issue identified.

“We have clear plans in place to tackle compliance at our sites, which includes increasing our own inspections and the deployment of more technology to identify potential issues before they impact our operations or the environment.

A Northumbrian Water spokesperson said: “We welcome the Environment Agency’s inspections and work closely with them to make sure our wastewater sites continue to operate as they should.

“During these visits, no serious issues have been reported. Where actions are identified, they are usually minor, such as labelling or routine maintenance requirements, and low risk for pollution or environmental harm. We’re open with the Environment Agency and keep them updated as actions are completed.

“We’re committed to improving our performance and between 2025 and 2030 we are investing £1.7bn on environmental improvements. These are helping to reduce the number of spills from storm overflows and improve our coasts and rivers.”

A United Utilities spokesperson said: “We continue to work constructively and openly with the Environment Agency and our other regulators. We take proactive action whenever issues arise and continually strive to improve our operational performance. Our focus remains on delivering our environmental investment programme and meeting the high standards our customers and regulators rightly expect.”

British companies are investing less in their domestic economy than almost any of their G7 counterparts, reinforcing long-standing concerns about productivity and growth as rising energy costs add fresh pressure on industry.

Analysis from Institute for Public Policy Research (IPPR) shows that private sector investment in the UK amounted to just 11.1 per cent of GDP in 2023, the second-lowest level in the G7, ahead only of Canada at 10.8 per cent.

By comparison, Japan leads the group with investment equivalent to 18.2 per cent of GDP, followed by France at 12.6 per cent and Germany at 11.9 per cent, highlighting the scale of the UK’s relative underperformance.

The findings underline a persistent structural issue. The UK has consistently ranked near the bottom of the G7 for business investment since the global financial crisis, and has remained below the group average every year since 2001.

According to the IPPR, this chronic underinvestment has constrained productivity growth for years, limiting the ability of businesses to expand capacity, adopt new technologies and improve efficiency.

One of the clearest indicators of this gap is capital intensity, the amount of equipment and infrastructure available to workers.

The report estimates that UK workers have 38 per cent fewer tools at their disposal than their counterparts in other advanced economies, rising to 47 per cent in manufacturing sectors. This shortfall, often referred to as the “capital gap”, is seen as a major drag on productivity and competitiveness.

High energy prices are identified as a central factor holding back investment. UK businesses face some of the highest electricity costs in Europe, a situation that has worsened following the recent surge in global gas prices linked to geopolitical tensions in the Middle East.

Pranesh Narayanan, a senior research fellow at the IPPR, said companies are caught in a “double squeeze”.

“Businesses are investing too little while also facing some of the highest electricity costs in Europe, and the two are closely linked,” he said.

Rising energy costs not only increase operating expenses but also reduce the incentive to invest in new facilities or equipment, particularly in energy-intensive industries.

The report calls for adjustments to the government’s planned British Industrial Competitiveness Scheme (BICS), which aims to reduce electricity costs for around 7,000 factories by up to 25 per cent when it launches in 2027.

The IPPR argues that the scheme should be more targeted, focusing on sectors where lower energy costs are most likely to unlock new investment and drive long-term growth.

“With limited fiscal room, support should be directed where it can generate new factories, new equipment and new jobs,” Narayanan said.

The UK’s low investment rate has significant implications for economic performance. Without sufficient capital investment, businesses struggle to improve productivity, which in turn limits wage growth and overall economic expansion.

The issue is particularly acute at a time when the economy is facing additional headwinds from inflation, higher borrowing costs and global uncertainty.

The latest findings reinforce the urgency of addressing the UK’s investment gap, particularly as global competition intensifies and technological change accelerates.

While policy initiatives aimed at reducing energy costs and supporting industry could help, the scale of the challenge suggests that a broader, long-term strategy will be required.

For businesses, the decision to invest will depend on confidence in the economic environment and the cost of operating in the UK. For policymakers, the task is to create conditions that make such investment both viable and attractive.

Without a sustained improvement, the UK risks remaining stuck in a cycle of low investment, weak productivity and subdued growth, a challenge that has persisted for more than a decade.

Jamie Young

Jamie is Senior Reporter at Business Matters, bringing over a decade of experience in UK SME business reporting.
Jamie holds a degree in Business Administration and regularly participates in industry conferences and workshops.

When not reporting on the latest business developments, Jamie is passionate about mentoring up-and-coming journalists and entrepreneurs to inspire the next generation of business leaders.

Advertisement

Shares of Cyclerion Therapeutics Inc. skyrocketed more than 313% Wednesday, surging from around $1.55 at Tuesday’s close to trade near $6.47 midday as the micro-cap biotech announced a transformative all-stock merger with privately held Korsana Biosciences Inc.

The explosive move came after Cyclerion and Korsana revealed a definitive merger agreement early Wednesday morning, alongside Korsana’s concurrent $380 million oversubscribed private financing. The deal positions the combined company — to be renamed Korsana Biosciences and trade under the ticker “KRSA” — to advance a promising pipeline of next-generation therapies for neurodegenerative diseases, starting with Alzheimer’s.

Volume exploded to more than 213 million shares by midday, dwarfing the company’s typical trading activity and reflecting intense retail and institutional interest in the rare biotech reversal story. Pre-merger Cyclerion shareholders are expected to own roughly 1.5% of the post-deal entity, with Korsana stakeholders (including new financing participants) claiming about 98.5%, subject to net cash adjustments.

“This transaction represents the best path forward for Cyclerion following a comprehensive strategic review,” said Regina Graul, Ph.D., president and CEO of Cyclerion. “Korsana’s promising and innovative pipeline targeting neurodegenerative disorders, beginning with Alzheimer’s disease, provides the potential for significant value creation for Cyclerion’s shareholders.”

Korsana’s lead program, KRSA-028, is a next-generation shuttled monoclonal antibody targeting amyloid beta for Alzheimer’s. It leverages the proprietary Therapeutic Targeting (THETA™) platform, designed to achieve higher brain concentrations while reducing risks such as amyloid-related imaging abnormalities (ARIA) and enabling convenient low-volume subcutaneous dosing.

Deal Details and Strategic Shift

The all-stock merger, approved by both boards, is expected to close in the third quarter of 2026. It remains subject to stockholder approvals, SEC registration effectiveness, Hart-Scott-Rodino antitrust clearance and other customary conditions.

Upon closing, the combined company will operate as Korsana Biosciences Inc., led by Jonathan Violin, Ph.D., as CEO. The board will be chaired by Tomas Kiselak of Fairmount, with directors including representatives from Venrock, Wellington Management and others.

Korsana, which emerged from stealth in February 2026 after raising $175 million in prior rounds (seed from Fairmount and Venrock, plus a $150 million Series A), brings substantial backing from top-tier investors. The new $380 million private placement, led by Fairmount and Venrock Healthcare Capital Partners with participation from General Atlantic, TCGX, Forbion, Wellington, RA Capital, RTW, Vivo, Janus Henderson, Foresite, J.P. Morgan Life Sciences, Sanofi Ventures and others, is expected to extend the combined company’s cash runway into 2029.

Proceeds will fund advancement of KRSA-028, with Phase 1 healthy volunteer data anticipated in mid-2027 and interim proof-of-concept data for amyloid plaque clearance in Alzheimer’s patients by the end of 2027.

Korsana, the seventh company launched from assets developed by Paragon Therapeutics, also maintains a broader pipeline using the THETA™ platform for other undisclosed neurodegenerative conditions with high unmet need.

For Cyclerion, the move marks a sharp pivot. The Cambridge, Massachusetts-based company had been focused on neuropsychiatric therapies, particularly CYC-126 — an anesthetic-based, EEG-guided treatment for treatment-resistant depression (TRD). Recent milestones included positive FDA feedback in February 2026 on its Phase 2 proof-of-concept study plans and a strategic collaboration with Medsteer for closed-loop delivery technology.

Cyclerion had also been monetizing legacy soluble guanylate cyclase (sGC) assets, including out-licenses generating milestone payments. However, with a tiny market capitalization and going-concern warnings in recent filings, the merger with a well-capitalized private player offered a lifeline and potential upside for remaining shareholders despite heavy dilution.

Market Reaction and Investor Sentiment

The 313% surge turned Cyclerion into one of the market’s biggest percentage gainers on April 1, drawing comparisons to other reverse-merger or SPAC-like biotech deals that have delivered quick pops followed by volatility.

Trading forums and social media buzzed with commentary ranging from excitement over the Alzheimer’s angle — amid ongoing interest in amyloid-targeting therapies post-approvals of drugs like Leqembi and Kisunla — to caution about the extreme dilution and execution risks ahead.

Analysts noted that while the deal brings fresh capital and a more advanced pipeline, Cyclerion’s pre-deal shareholders face significant ownership dilution. The stock’s micro-cap status and history of volatility (it has traded as low as around $1 in recent months after earlier surges tied to the TRD pivot) underscore the high-risk nature of the name.

Alzheimer’s Landscape and Korsana’s Differentiation

Korsana enters a competitive but rapidly evolving Alzheimer’s field. Existing anti-amyloid antibodies have shown plaque-clearing benefits but face challenges with safety (ARIA-related brain swelling or microbleeds) and administration (often requiring intravenous infusions).

KRSA-028 aims to stand out through THETA™ technology, which combines transferrin receptor (TfR1) shuttling with Fc engineering for better blood-brain barrier penetration, potentially lower side effects and subcutaneous convenience. Korsana executives believe this could translate to a best-in-class profile.

“Patients deserve better options than what is currently available, and we believe our lead program KRSA-028 can deliver a best-in-class product to treat Alzheimer’s disease,” Violin said. “We are also building a broader pipeline leveraging our proprietary platform to target other devastating neurodegenerative disorders.”

The broader neurodegenerative space remains one of biotech’s highest unmet needs, with aging populations driving demand and investors rewarding companies that can demonstrate differentiated mechanisms or improved safety.

What’s Next for the Combined Company

A conference call was scheduled for Wednesday morning to discuss the transaction. Investors will watch for updates on integration, detailed clinical timelines and any adjustments to ownership percentages based on Cyclerion’s net cash position.

Closing in Q3 2026 would allow the new entity to focus fully on Korsana’s pipeline while maintaining Nasdaq listing continuity under the new ticker.

Risks remain substantial. Clinical development in Alzheimer’s is notoriously challenging, with many programs failing despite promising preclinical data. Regulatory hurdles, competition from larger players and potential integration issues could pressure the stock post-deal.

Cyclerion’s legacy TRD assets and sGC portfolio may be evaluated for further monetization or out-licensing as the company shifts focus.

Broader Context in Biotech M&A

The deal fits a pattern of cash-strapped public biotechs merging with well-funded private innovators to access capital markets and extend runways without traditional IPOs in a selective funding environment. Such reverse mergers can provide liquidity events for private investors while offering public shareholders a reset — albeit often at the cost of heavy dilution.

For retail traders, names like CYCN have occasionally delivered dramatic short-term moves on catalyst-driven days, though sustainability depends on clinical execution.

As of midday Wednesday, the surge showed signs of volatility typical of low-float, high-volume sessions. Longer-term performance will hinge on milestones for KRSA-028 and the strength of the THETA™ platform.

Cyclerion, originally spun out of Ironwood Pharmaceuticals in 2019, has navigated multiple strategic shifts over the years. Wednesday’s announcement could mark its most significant transformation yet.

Investors should monitor official filings, the upcoming registration statement and any post-merger updates from the combined leadership team.

While the April 1 surge provided a dramatic headline, the real test for value creation lies in the clinic and the ability to deliver meaningful advances against neurodegenerative diseases that affect millions worldwide.

Shares of Axe Compute Inc. more than doubled Wednesday, surging as much as 102% to trade around $3.32 midday after the company announced $12 million in newly executed agreements expected to generate roughly $835,000 in monthly recurring revenue as it ramps up its enterprise GPU infrastructure business.

The explosive move came on the heels of the company’s fiscal 2025 earnings release late Tuesday and a morning conference call discussing its full pivot from legacy drug discovery operations to AI compute services. Volume spiked dramatically, with tens of millions of shares changing hands in the first hours of trading as retail investors piled into the micro-cap name amid broader enthusiasm for AI-related infrastructure plays.

Axe Compute, which rebranded from Predictive Oncology Inc. in December 2025 and began trading under the ticker AGPU, reported signing contracts with more than 20 enterprise customers over the past 30 days. The deals, focused on reserved GPU capacity for production AI workloads, are projected to deliver approximately $7.5 million in estimated 2026 revenue at the current run rate once deployments begin entering the second quarter.

“This $12 million book we’ve built entering Q2 is not a marketing milestone — it is executed agreements from enterprises with production AI workloads,” CEO Christopher Miglino said in a statement. The company highlighted its Strategic Compute Reserve, which provides access to over 435,000 GPUs globally through partnerships including the Aethir network, enabling rapid 24- to 48-hour deployments across more than 200 locations without vendor lock-in.

Financial Results Reflect Transition Costs

For the full year 2025, Axe Compute posted revenue of just $125,284 — all from its legacy drug discovery services segment — with no meaningful compute revenue yet recognized. The company reported a massive net loss of $232.9 million to $233.1 million, driven largely by $152.5 million in unrealized losses on its ATH digital asset holdings and $52.7 million in derivative instrument losses, plus elevated operating expenses tied to the strategic repositioning.

Despite the headline loss, executives pointed to significant balance sheet progress. Through PIPE transactions closed in October 2025, the company raised approximately $343.5 million in a mix of cash and in-kind ATH token contributions. This infusion, combined with other actions including a reverse stock split, restored Nasdaq compliance and rebuilt stockholders’ equity to $47.7 million from a prior deficit. Cash stood at $10.8 million at year-end, with additional unlocked ATH tokens valued at $24.4 million.

Miglino, who joined as CEO in February 2026, framed 2025 as a foundational year. “In less than 90 days, we raised $343.5 million in capital, established a Strategic Compute Reserve through a digital asset treasury position in the ATH AI token, and reconstituted our balance sheet,” he noted on the earnings call.

Strategic Pivot to Decentralized AI Compute

Axe Compute is positioning itself as a flexible provider of GPU-as-a-Service for enterprises and developers seeking scalable, cost-efficient AI infrastructure. By leveraging decentralized networks like Aethir, the company aims to offer choice in hardware mixes while avoiding the lock-in common with major cloud providers.

Key elements of the strategy include:

• Strategic Compute Reserve: A GPU capacity platform launched in September 2025 that allows quick deployment for AI, machine learning, gaming and rendering workloads.
• ATH Treasury Model: Holding and potentially staking the Aethir token to generate yield, creating a revenue-backed infrastructure approach.
• Enterprise Focus: Prepayment-based contracts with diverse customers, currently boasting 30-plus active deployments.

The company also continues exploring strategic alternatives for its Helomics drug discovery and biobank business, including potential sale, partnership or licensing, to sharpen focus on the higher-growth AI compute opportunity.

In March 2026, Axe Compute bolstered its board with technology and telecom veterans Dr. Theodore Zhu and Thorsten Dirks, adding expertise in semiconductors, neural networks, international operations and corporate transformation.

Market Reaction and Investor Sentiment

The more-than-doubling of the stock on April 1 reflected investor excitement over tangible contract momentum in a red-hot AI sector, even as the company remains pre-revenue in its core new business. Trading forums and social platforms saw heightened discussion, with some users highlighting the contracts’ size relative to the company’s prior market capitalization.

Analysts and observers cautioned that execution risks remain high. The company faces challenges typical of micro-cap pivots: delivering on deployments, managing digital asset volatility, scaling operations and navigating competition from established cloud giants and other decentralized compute players.

Still, the forward guidance — including expectations of initial compute services revenue in 2026 and potential EPS of around 45 cents in some projections — offered a narrative of inflection. The stock has traded in a wide range historically, with a 52-week span reflecting earlier volatility tied to the rebranding and capital raises.

Broader AI Infrastructure Context

Axe Compute enters a booming market for GPU capacity driven by exploding demand for training and inference in generative AI. Enterprises increasingly seek alternatives to hyperscaler dominance, creating openings for agile providers offering flexible, geographically distributed resources.

The integration of digital asset treasury strategies adds a novel layer, potentially allowing the company to generate yield on holdings while funding infrastructure expansion. However, it also introduces crypto-related volatility, as evidenced by the large non-cash losses tied to ATH price movements in 2025.

Industry watchers note that success will hinge on rapid deployment, customer retention and demonstrating differentiated value through speed, cost and choice. Partnerships like Aethir provide immediate scale, but long-term differentiation will require strong execution on service quality and innovation.

Outlook and Priorities for 2026

Management outlined clear 2026 priorities:

1. Deploy reserved GPU capacity and generate initial compute services revenue.
2. Pursue staking and yield opportunities on the ATH treasury position.
3. Complete the strategic review of the legacy Helomics business.
4. Selectively add to the digital asset treasury via open-market purchases when conditions allow.

The April 1 announcement of signed contracts marks an early validation of the model, with management expressing confidence that the pipeline will expand as deployments ramp and word spreads among AI workload owners.

For investors, the name carries substantial risk given its small size, history of losses, reliance on digital assets and pre-profit stage in the new segment. Those following the story will watch upcoming quarterly updates for evidence of deployment progress, revenue recognition and margin trends.

Axe Compute, headquartered in Pittsburgh with roots in earlier medical and oncology-focused operations, now bets its future on powering the AI economy. Wednesday’s surge provided a dramatic spotlight on its ambitions, but sustained gains will depend on converting contracts into reliable cash flows amid fierce competition.

As midday trading continued, the stock showed typical volatility for a low-float, high-momentum session. Longer-term performance will be determined by the company’s ability to scale its GPU platform while prudently managing its evolving balance sheet.